X enogeneic islet transplantation has long been investigated as a future therapeutic option for diabetic patients. Pig islets may be ideal for xenogeneic islet transplantation due in part to the biochemical compatibility between porcine and human insulin, and to the potential availability of large numbers of donor pigs through relatively short turnaround farming strategies. An additional theoretical advantage of pig islets is their potential resistance to recurrence of autoimmunity directed against human β cells. 1 Antibody responses have constituted a major barrier in transplants between phylogenetically distant (discordant) species, such as pig-to-human transplantation, and result in hyperacute rejection due to preformed xenogeneic antibodies. With recent advances in the identification of carbohydrate xenoantigens, 2 and genetic engineering that enables elimination of such xenoantigens, 3 prevention of hyperacute rejection may now be achieved.
However, T cell-mediated xenogeneic immune responses are vigorous and more difficult to control than those towards alloantigens. 4 Currently, xenogeneic islet transplant requires aggressive immunosuppression, rendering the risk-benefit profile unfavorable to justify its substitution for daily insulin.
Xenogeneic T cell responses to pig islets can be triggered by both direct and indirect antigen presentation. 5 Once activated, T cells can mediate graft destruction by direct cytotoxicity, 6 or by differentiation to cytokine-producing T helper cells that provide B cell help for class switching and antibody production, or by activating innate cells such as macrophages and NK cells that participate in xenograft rejection. 7, 8 Both Th1 and Th2 cytokines, such as IFN-γ and IL-4, have been reported in xenogeneic rejection. [9] [10] [11] However, the role of IL-17 in xenogeneic rejection has not been studied. Recently, this cytokine has been implicated in allograft rejection, 12 especially during early rejection response as shown in human heart transplant recipients 13 where it promotes leukocyte trafficking, 14 induces B cell differentiation and antibody production, 15 and enhances graft fibrosis. 16, 17 In an attempt to develop strategies for tolerance induction for xenogeneic islet transplantation, we used our effective strategy for tolerogenic alloantigen delivery via apoptotic ethylenecarbodiimide (ECDI)-fixed donor cells, [18] [19] [20] and modified it to apply to tolerogenic xenoantigen delivery for xenogeneic islet transplantation. Silent clearance of apoptotic cells exerts potent immune-regulatory effects. 21, 22 Consequently, infusion of ECDI-fixed donor splenocytes (ECDI-SP) effectively induces donor-specific tolerance. 19, [23] [24] [25] In murine models, ECDI-SP induce tolerance to islet allografts, 18, 19, 26, 27 and when combined with short-term rapamycin or anti-CD20, also to heart allografts 20, 28, 29 and to concordant (rat-to-mouse) islet xenografts, 30 respectively. More importantly, a first-in-human clinical trial using ECDI-fixed peptide-coupled autologous peripheral blood mononuclear cells has recently been conducted in patients with multiple sclerosis, demonstrating the clinical feasibility, tolerability and safety of this novel tolerogenic strategy. 31 In the current study, we used a discordant pig-to-mouse xenogeneic islet transplant model to study the mechanisms of early and late rejection of pig islet xenografts in mice, and to test the efficacy of pig ECDI-SP in inducing discordant xenogeneic tolerance.
MATERIALS AND METHODS

Animals and Induction of Diabetes
Male C57BL/6 (B6), BALB/c mice, and B6.Foxp3-DTR/ eGFP mice, all 7 to 10 weeks old, were purchased from The Jackson Laboratory. Donor pigs were retired wild-type breeders aged 18 months or older. Pig splenocytes and 6-day to 9-day cultured islets were provided by the Schultz Diabetes Institute, University of Minnesota. Diabetes was induced by injection of 200 mg/kg streptozotocin (Sigma) and confirmed by blood glucose greater than 250 mg/dL on 2 consecutive days. All studies were approved by Northwestern University and the University of Minnesota ACUC.
Islet Transplantation
Three thousand pig islet equivalents, 200 BALB/c or B6 islets were transplanted under the kidney capsule of diabetic B6 mice. Rejection was diagnosed when blood glucose was greater than 250 mg/dL for 2 consecutive days.
Transplant Recipient Treatment
ECDI-treated pig splenocytes were prepared as described. 18 10 8 ECDI-SP in 200 μL phosphate-buffered saline were injected on days −7 and +1, with day 0 being the day of islet transplantation. In recipients treated with anti-CD20, 250 μg of anti-CD20 (clone 5D2; Genentech) was administrated intarvenously on days −9 and 0 in recipients receiving pig ECDI-SP, or day 0 in recipients not receiving pig ECDI-SP. The additional dose of anti-CD20 on day −9 for pig ECDI-SPtreated recipients was given to inhibit the induction of antixenogeneic antibodies by xenogeneic ECDI-SP itself as we have shown previously. 30 In selected groups, rapamycin (rapa, 1 mg/kg daily) was administrated intraperitoneally (i.p.) from day −8 to +10. Anti-IL-17A (clone 17F3; BioXCell) or mouse IgG1 (clone MOPC-21; BioXCell) was administrated at 100 μg/day i.p. from day 0 to 13. Anti-GM-CSFR (clone CAM3003) was injected at 600 μg/2 days i.p. from day 0 to 20 based on published report using this antibody. 32 Anti-CD25 (clone PC-61, BioXCell) was injected at 0.5 mg/dose on day −9 and −7. Diphtheria toxin (Sigma) was dissolved in dH 2 O, and injected i.p. at 10 μg/kg in triple therapy-treated and pig islettransplanted B6.Foxp3-DTR/EGFP mice on days −9, −8, −6, −4, −2 and 0, with day 0 being the day of pig islet transplantation.
Mouse Antipig Antibody Measurement
Sera were obtained from recipients 14-21 days after rejection. Sera were heat-inactivated at 56°C for 30 min, followed by incubation with donor pig splenocytes on ice for 1 hr. After washing, pig splenocytes were stained with fluorescein isothiocyanate-conjugated rat antimouse IgM (clone R6-60.2), IgG1 (clone A85-1), IgG2a (clone R19-15), IgG2b (clone R12-3), or IgG3 (clone R40-82) mAbs (all from BD Biosciences) and analyzed by fluorescence-activated cell sorting (FACS). Sera from naive B6 served as negative control. 
Intracellular Staining
T cells were co-cultured as above for 5 days. Immediately before harvesting, cells were further stimulated with leukocyte activation cocktail (eBioscience) for 4 hours followed by staining with vFluor 450-anti-mCD4 (RM4-5, TONBO) and PercpCy5.5-anti-mCD8 (53-6.7, TONBO), fixed and permeabilized, and stained with PE-anti-mIL-17A (eBio17B8, eBioscience) or PE-Cy7-anti-mIFN-γ (XMG1.2, TONBO).
Delayed-Type Hypersensitivity Assay
Delayed-type hypersensitivity (DTH) assays were performed as described. 18 Briefly, the ear thickness of mice was measured with a Mitutoyo engineer's micrometer (Schlesinger's Tools) immediately before injection of 10 7 pig splenocyte lysate in 10 μL PBS into the dorsal surface of the ear. 24 hours later, the ear thickness was measured and increase over baseline was determined.
Real Time PCR
Xenografts were peeled off from the kidney capsule of recipients 10-14 days after transplantation. Total RNAs were isolated using RNeasy kit (Qiagen) and cDNA was synthesized using a high-capacity cDNA archive kit (Lifetechnologies/ Applied Biosystems). Expression levels of IL-17A (Assay ID: Mm00439618_m1), RORγC (Assay ID: Mm01261022_m1), and IFN-γ (Assay ID: Mm01168134_m1) mRNA were quantified using TaqMan Universal PCR master mix (Lifetechnologies/Applied Biosystems). GAPDH was used as an endogenous reference. Data was analyzed using ABI 7500 Sequence Detection software.
Histology
Frozen sections (10 μm) of islet grafts were blocked with 10% donkey serum (Sigma-Aldrich), stained with rat antimouse B220 mAb (1:250, rIgG2a κ, clone RA3-6B2; eBiosciences), guinea pig anti-insulin pAb (1:200, DAKO A0564), or rat antimouse Foxp3 mAb (1:200, rIgG2a, clone FJK-16; eBiosciences), and visualized with donkey antirat DyLight 594 (1:500; Jackson ImmunoResearch) and/or donkey antiguinea pig Alexa 488 (1:250, Jackson ImmunoResearch). DAPI staining was concurrently performed. Images were visualized using Leica DM5000 B microscope, acquired with a QImaging Retiga 4000r camera, and analyzed with Image Pro 6.2 software.
Statistical Analysis
Graft survival was compared using Kaplan-Meier survival curves with log-rank test. Statistical significance between 2 groups was determined by Wilcoxon nonparametric tests or unpaired t tests. Data representing more than 2 groups were analyzed with one-way analysis of variance. All statistical analyses were performed using GraphPad Prism 5 software.
RESULTS
B Cells Play A Critical Role During Early Rejection of Pig Islet Xenografts in Mice
A discordant pig-to-C57BL/6 (B6) mouse xenogeneic islet transplant model was used. In this model, un-treated B6 recipients rejected pig islets between day 7 and 26 posttransplantation ( Figure 1A ). We first examined the histology of the rejecting pig islet xenografts. To our great surprise, we observed prominent graft-infiltrating B cells around the time of acute rejection (day 14 posttransplant, Figure 1B ). This is in sharp contrast to rejecting BALB/c islet allografts in which B cell infiltration was minimal ( Figure S1 , SDC, http://links. lww.com/TP/B352). Recipients that rejected their islet xenografts also exhibited prominent antipig antibody production, particularly of IgG1, IgG2a and IgG2b isotypes ( Figure 1C ). Consequently, when recipient were depleted of B cells at the time of transplant, a significant prolongation of pig islet xenograft survival was observed ( Figure 1D ). Collectively, these findings suggest that B cells play an important role in early acute rejection of discordant pig islet xenografts in mice.
IL-17 Is The Predominant Antidonor T Cell Cytokine Response During Early Rejection of Pig Islet Xenografts in Mice
It has been shown that B cells can effectively prime Th17 immune response. [33] [34] [35] Given that B cells play a critical role in early acute rejection of pig islet xenografts in mice (Figure 1 ), we next examined if T cell IL-17 response was induced during acute rejection. As shown in Figure 2A (open bars), T cells from hosts rejecting pig islet xenografts showed a robust donor-stimulated IL-17 response measured by ELISPOT assays compared with naive mice. Surprisingly, these T cells did not exhibit a significant IFN-γ response. This is in sharp contrast to the T cell response from hosts rejecting islet allografts (BALB/c → B6) in which a robust antidonor IFN-γ, but only minimal IL-17, response was observed ( Figure 2A , filled bars). We next determined if IL-17 was also produced at the site of the rejecting pig islet xenografts. As shown in Figure 2B , rejecting xenogeneic islets exhibited a markedly elevated level of IL-17A mRNA, but not IFN-γ mRNA. In contrast, rejecting allogeneic islets exhibited an elevated level of IFN-γ mRNA, but not IL-17A mRNA. We verified in a second murine recipient strain BALB/c that intra-graft IL-17-producing cells were also present in rejecting pig islet xenografts ( Figure S2 , SDC, http://links.lww.com/TP/B352), confirming that this response is common to both Th1 (B6) and Th2 (BALB/c) biased recipient strains. Lastly, we determined if neutralizing IL-17A had any beneficial effect on the survival of islet xenografts. As shown in Figure 2C , neutralization of IL-17A at the time of transplant allowed a transient prolongation of pig islet xenograft survival. IL-17-producing cells have also been shown to secrete GM-CSF to mediate Th17-driven inflammation in disease models such as experimental autoimmune encephalitis. 36 Therefore, we next tested if blocking GM-CSF was also protective to pig islet xenografts. As shown in Figure 1C , recipient treated with a course of GM-CSF receptor blocking antibody (anti-GM-CSFR) also exhibited a significant prolongation of pig islet xenograft survival. Collectively, these findings suggest a nonredundant role of IL-17 during early rejection of pig islet xenografts. However, the rather transient protection provided by anti-IL17 or anti-GM-CSFR indicates that other parallel IL-17-independent mechanisms also exist. To identify which stimulatory pathway (direct vs. indirect) is predominantly driving the xenogeneic IL-17 response, we co-cultured T cells from above rejecting B6 hosts either with irradiated donor pig splenocytes alone (direct pathway) or with irradiated syngeneic B6 splenocytes pulsed with donor pig cell lysates (indirect pathway), and measured IL-17 production by ELISPOT. As shown in Figure 3A , both direct and indirect stimulation of T cells from rejecting hosts resulted in robust IL-17 responses. To determine which T cell compartment produced IL-17, we performed intracellular staining of the above-stimulated T cells. As shown in Figure 3B , both CD4 and CD8 T cells were able to produce IL-17 upon either direct or indirect donor stimulation.
B Cell Depletion in Combination With Donor ECDI-SP Significantly Prolong Pig Islet Xenograft Survival in Mice
Because B cell depletion alone only led to a transient graft protection ( Figure 1C ), we next searched for a combinatorial regimen with additional tolerance-promoting therapies to achieve long-term pig islet xenograft protection. Previously, we have demonstrated that peri-transplant infusion of donor ECDI-SP induces robust allogeneic donor-specific tolerance via parallel mechanisms including induction of T cell anergy, deletion and regulation. 18, 20, 30 We therefore tested the tolerance efficacy of donor ECDI-SP in the pig-to-mouse model. We first used a pig-to-mouse DTH model. We immunized mice with pig splenocyte lysates mixed with complete Freund's adjuvant (CFA) on day 0, either with or without intravenous injection of 10 8 same-donor pig ECDI-SP on day −7 and day +1, and measured donor-stimulated cytokine response on day 14. As shown in Figure 4A , pig ECDI-SP treatment inhibited host antipig IL-17 response by approximately 50% compared with untreated controls. Corresponding to this inhibition, pig ECDI-SP treatment also significantly inhibited host DTH response ( Figure 4B ). We next combined B cell depletion with pig ECDI-SP treatment (dual therapy) in the same model, and observed that this combination led to a remarkable further suppression of host antipig IL-17 response ( Figure 4A ), indicating that B cells play a significant role in the priming of the early host antipig IL-17 response.
Next, we tested the efficacy of the dual therapy in the pig-to-mouse islet transplant model. As shown in Figure 4C , donor ECDI-SP alone did not prolong pig islet xenograft survival. However, when combined with B cell depletion, the dual therapy substantially prolonged pig islet xenograft survival beyond that seen with anti-CD20 alone ( Figure 1C ), leading to approximately 40% graft survival beyond 100 days ( Figure 4C) . Lastly, based on our published report showing a synergistic graft-protective effect between donor ECDI-SP and rapamycin, 20 we further added a short course of peritransplant rapamycin to the dual therapy. The resulting triple therapy resulted in a further increase of long-term (>100 days) graft survival rate to approximately 65% ( Figure 4C) .
In recipients treated with the above triple therapy, we also quantified IL-17 production in the islet xenografts and the spleen. Harvested on day 14 posttransplantation, pig islet xenografts from triple therapy treated recipients exhibited markedly suppressed IL-17A and RORγC mRNA levels compared with those from control un-treated recipients ( Figure 4D ). Next, splenic T cells from transplant recipients were harvested on days 21, 40, and 78 posttransplant, and the magnitude of IL-17 response by indirect donor stimulation was measured. As shown in Figure 4E , triple therapy treatment robustly suppressed host antipig IL-17 response early on (day 21 posttransplantation), and persisted to over 78 days posttransplant. Collectively, these data suggest that pig ECDI-SP, when combined with transient B cell depletion and rapamycin, results in a significant and sustained inhibition of host antipig IL-17 response, and a significant prolongation of pig islet xenograft survival. In recipients with islet xenograft survival longer than 100 days, retrieval of the transplanted pig islet xenograft precipitated immediate hyperglycemia (data nor shown). Retrieved long-term functioning pig islet xenografts showed well-preserved islet structure ( Figure 5A ). Clusters of lymphocytes were seen surrounding the intact islets without infiltrating into and destructing the islets. These clusters of + B cell infiltration during acute rejection of pig islet xenografts. Pig islet xenografts were retrieved on day 14 posttransplantation, processed and stained as described in Materials and Methods. Left panel: hematoxylin and eosin staining, 10Â; Right panel: immunofluorescent staining, blue = DAPI, red = B220. Data shown Are representative of 3 to 5 pig islet xenografts examined. C, Anti-pig xenogeneic antibodies in recipients that have rejected the pig islet xenograft. Sera from recipient mice were obtained 20 days after confirmed graft rejection and examined for anti-pig xenogeneic antibodies by FACS analysis (line histogram) as described in Materials and Methods, and compared with those from naive mice (shaded histogram). Results shown are representative of those from 5 mice. D, Pig islet xenograft survival in diabetic B6 recipients either with or without B cell depleting antibody anti-CD20. Recipient treatment with anti-CD20 is described in Materials and Methods. "Control": mice transplanted with pig islet xenografts in the absence anti-CD20 treatment; "anti-CD20": mice transplanted with pig islet xenografts in the presence of anti-CD20 treatment. **P = 0.0093. IEQ, islet equivalent.
lymphocytes were highly enriched for Foxp3 + cells ( Figure 5A ). To determine if Foxp3 + regulatory T (Treg) cells were important for graft protection, we performed 2 lines of experiments. First, we injected recipients with anti-CD25 (clone PC-61) to deplete CD25 + cells around the time of transplantation. As shown in Figure 5B , left panel, depletion of CD25 + cells significantly impaired graft protection in recipients treated with the triple therapy. To more specifically deplete Foxp3 + Treg cells, we used Foxp3-DTR/eGFP mice as recipients. Recipients were treated with DT to deplete Foxp3 + Treg cells at the time of transplantation. As shown in Figure 5B , right panel, depletion of Foxp3 + Treg cells resulted in rapid rejection of pig islet xenografts in recipients treated with the triple therapy. Of note, pig islets are likely resistant to direct DT toxicity, because 1 the pig islets in DT-treated recipients survived for over 10 days after the last dose of DT ( Figure 5B) ; and 2 published literature support that pig cells are resistant to DT unless DT is guided to the targeted cells by ligand-receptor binding via DT fusion proteins. 37 Collectively, these data suggest that Treg cells play a critical role in promoting and maintaining pig islet xenograft survival seen in recipients treated with the triple therapy.
Late Rejection of Pig Islet Xenografts Is Associated With Heavy B Cell Graft Infiltration and Antidonor IFN-g Response
In our cohort of triple therapy treated recipients, we observed that a significant portion of them (~80%) experienced late rejection between day 100 and 200 posttransplantation ( Figure 6A ).
We first examined the histology of late rejecting islet xenografts around the time of rejection. To our great surprise, these grafts were aggressively infiltrated with a large number of B220 + B cells ( Figure 6B ), presumably after B cell reconstitution after anti-CD20 depletion.
We next measured antipig antibodies in these recipients after late rejection. Sera were collected 20 days after confirmed graft rejection. As shown in Figure 6C , there was minimal antipig antibody production in all Ig subclasses in these recipients. This is in sharp contrast to untreated recipients that rejected their islet xenografts early on ( Figure 1C) , in which robust antipig antibodies could be detected. These data indicate that returning B cells participate in late rejection of islet xenografts at the site of the graft in a capacity that is beyond their role in promoting antibody production.
Lastly, we examined the antidonor T cell response during late rejection. Splenic T cells from triple therapy treated recipients were harvested on day 98 and 159 posttransplant and examined for donor-stimulated cytokine production. As shown in Figure 6D , T cells from triple therapy treated recipients on day 98 and day 159 showed a marked increase in antipig IFN-γ response compared with that seen early on (days 21, 41, and 75 posttransplant), whereas antipig IL-17 response remained suppressed throughout. This increase of antipig IFN-γ response was primarily observed with indirect ( Figure 6D , left bar graph) but not direct ( Figure 6D , right bar graph) donor stimulation, consistent with the notion that indirect immune response predominates as donor passenger leukocytes dissipate.
DISCUSSION
In the current study, we show that during early rejection of pig islet xenografts in mice, direct and indirect antidonor IL-17 responses as well as xenogeneic antibody production play an important role, and that B cells likely contribute to the priming of both. In contrast, late rejection seen in triple therapy treated recipients is associated with indirect antidonor IFN-γ response preceded by B cell reconstitution and aggressive graft B cell infiltration, but a complete absence of xenogeneic antibody production.
The crucial role of B cells in early acute rejection of islet xenografts was unequivocally demonstrated by B cell depletion that resulted in substantial graft prolongation ( Figure 1D) . Based on the current study, the specific functions of B cells in xenogeneic rejection appear to be pleiotropic and timedependent. During early acute rejection, B cells likely contribute to the priming of IL-17-producing T cells and to the differentiation of xenogeneic antibody-producing plasma cells. It has been shown that B cell antigen presentation by B1 B cells can effectively promote Th17 differentiation. [33] [34] [35] Reciprocally, Th17 cells are effective B cell helpers and can induce B cell proliferation in vitro and trigger their class switching in vivo. 15 In our model, it is conceivable that the induced xenogeneic IL-17 response feeds back to promote B cell proliferation and differentiation. Consequently, a positive feedback loop between B cells and Th17 cells is established to effectively promote early acute rejection of islet xenografts.
A rather different picture of the role of B cells emerges during late rejection in recipients initially protected by the pig ECDI-SP + anti-CD20 + rapamycin triple therapy. First, late rejection appears to be exclusively cell-mediated, as xenogeneic antibodies remain undetectable during and after rejection of islet xenografts ( Figure 6C ). Secondly, late rejection appears to be invariably associated with an extremely aggressive B cell infiltration in the graft ( Figure 6B ). Thirdly, following B cell reconstitution, there is an ensuing emergence of indirect xenogeneic IFN-γ response ( Figure 6D ) preceding the late rejection. It is conceivable that the newly emerged B cells directly acquire xenogeneic antigens in the graft and prime indirect antidonor IFN-γ response. Graft-infiltrating B cells may also directly prime intra-graft cytotoxic T lymphocytes, 38 leading to in situ graft destruction. Future studies are necessary to elucidate the subtypes and functionality of the reconstituted B cells, specifically of graft-infiltrating B cells. Such an understanding will determine the choice of B cell-targeting therapies that will most effectively prevent late rejection.
During early acute rejection, the observed IL-17 response in the xenogeneic pig-to-mouse islet transplant model is in sharp contrast to that seen in full major histocompatibility complex-mismatched allogeneic mouse-to-mouse islet transplant model in which IFN-γ response dominates (Figure 2A ). Determining specific xenogeneic signals that trigger implicated APCs (eg B cells) to promote T cell IL-17, rather than IFN-γ, production will be beyond the scope of the current study. One possibility is xenogeneic carbohydrate antigens. Carbohydrate antigens have been shown to induce strong IL-17 production and exacerbate IL-17-mediated diseases, such as psoriasis. 39 This characteristic may explain the observed advantage of xenogeneic cancer cell-based vaccines over autologous or allogeneic vaccines. 40 Several possible pathways may be triggered by carbohydrate ligands, leading to enhanced IL-17 production. For example, carbohydrate ligands may conjugate with endogenous toll-like receptor ligands and enhance their immunostimulatory activity on toll-like receptors, 41, 42 leading to enhanced inflammation conducive for IL-17 production. Alternatively, carbohydrate may directly interact with lectin receptors and license lectin-bearing APCs to differentiate effector cells toward IL-17 production. [43] [44] [45] Although literature on carbohydrate-mediated skewing of Th17 differentiation is predominantly from models of infection, 46, 47 it has recently been shown that such a skewing may also play a role in transplantation rejection, such as graft-versus-host disease. 48 Recognition of xenogeneic carbohydrates by lectin receptors has been described in discordant xenogeneic transplantation models to promote phagocytosis of xenogeneic (human) erythrocytes and platelets by porcine macrophages. 49, 50 Interestingly, lectin receptor on CD4 T cells has also been associated with a propensity of their differentiation towards Th17 cells 51 and an increased risk for graft-versus-host disease. 52 Future dissection of the nature of xenoantigens in this process (eg, α-gal versus non-α-gal carbohydrates, swine leukocyte antigens versus non-swine leukocyte antigens), as well as determining the signaling requirements leading to xenogeneic IL-17 response will be imperative to shed light on potential therapeutic targets.
We have previously shown that donor ECDI-SP induce robust donor-specific T cell tolerance in models of allogeneic transplantation by parallel mechanisms including deletion, anergy, and regulation. 19 Others have also shown in models of autoimmunity and allergic diseases that ECDI-SP therapy can tolerize antigen-driven Th1, Th2, and Th17 responses. 21 The ability of inhibiting donor-stimulated T cell responses by donor ECDI-SP is recapitulated in the current pig-to-mouse islet transplant model during early graft protection. Thus, the surge of late donor-stimulated IFN-γ T cell response preceding late rejection was surprising. Further examination of the escape mechanisms of Th1 response in this model will be necessary to best select therapeutic targets to preserve long-term tolerance.
The current study used a pig-to-B6 xenogeneic islet transplant model. To exclude a strain-dependent effect, we performed similar experiments in BALB/c (Th2-biased) recipients, and confirmed that in a pig-to-BALB/c xenogeneic islet transplant model, similar IL-17 production during acute rejection was also observed, and that islet xenografts were similarly protected by pig ECDI-SP + anti-CD20 + rapamycin triple therapy ( Figure S2 , SDC, http://links.lww.com/TP/ B352). These results support the conclusion that our findings have a broader relevance that is not just restricted to Th1-biased (B6) recipients. Based on these studies and as a prelude to human studies, we are currently rigorously testing this tolerance protocol in a pig-to-monkey islet transplant model, the results of which will be summarized separately. Given the highly promising clinical translatability of this approach, 31 we believe that results obtained from our current study in this specific model demonstrating early and late immunological profiles will be highly valuable in guiding future designs of human tolerance protocols based on this specific approach. In summary, our studies demonstrate that pig ECDI-SP in combination with initial B cell depletion and a short course of rapamycin is highly effective in protecting pig islet xenografts beyond 100 days. A better understanding of the nature of B cells during their reconstitution and the escape mechanisms of the late Th1 response will likely provide the key to identifying effective therapeutic targets for durable xenogeneic tolerance to pig islets. FIGURE 6 . Late rejection of pig islet xenografts is associated with B cell graft infiltration and an emergence of antidonor IFN-γ response. A, Late rejection is observed between 100 and 200 days posttransplantation in a high percentage of islet xenograft recipients initially treated with ECDI-SP + anti-CD20 + rapamycin and showed > 100 days of islet xenograft survival. B, B220 + B cell infiltration during late rejection of pig islet xenografts. Pig islet xenografts were retrieved either at the time of or shortly after rejection was confirmed, processed and stained as described in Materials and Methods. Blue = DAPI, red = B220, magnification: 10Â. Data shown is representative of 3 to 5 pig islet xenografts examined. C, Antipig xenogeneic antibodies in recipients that have rejected the pig islet xenograft between 100 and 200 days. Sera from recipient mice undergoing rejection were obtained 20 days after confirmed graft rejection and examined for antipig xenogeneic antibodies by FACS analysis (line histogram) as described in Materials and Methods, and compared with those from naive mice 
